Given that this mouse model is a well-established model for human insulin resistance, diabetic dyslipidemia and NAFLD, and that concomitant GIPR/GLP1R agonism with tirzepatide was shown to lower NASH-related blood biomarkers in patients with type 2 diabetes,56 we anticipate that combined GIPR/GLP1R agonism is a promising strategy for the prevention/treatment of NAFLD in humans. The gene discussed is GIPR; the disease is metabolic dysfunction-associated steatotic liver disease.